JP2016535795A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016535795A5 JP2016535795A5 JP2016553270A JP2016553270A JP2016535795A5 JP 2016535795 A5 JP2016535795 A5 JP 2016535795A5 JP 2016553270 A JP2016553270 A JP 2016553270A JP 2016553270 A JP2016553270 A JP 2016553270A JP 2016535795 A5 JP2016535795 A5 JP 2016535795A5
- Authority
- JP
- Japan
- Prior art keywords
- chlorophenyl
- pharmaceutical composition
- oxopiperidin
- methylbutan
- isopropylsulfonyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 15
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 238000000034 method Methods 0.000 claims 8
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 6
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 6
- 201000001441 melanoma Diseases 0.000 claims 6
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 5
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 5
- -1 3-methyl-2-oxopiperidin-3-yl Chemical group 0.000 claims 4
- 230000035772 mutation Effects 0.000 claims 3
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 229960002465 dabrafenib Drugs 0.000 claims 2
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 claims 2
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 claims 2
- 229960004066 trametinib Drugs 0.000 claims 2
- DRLCSJFKKILATL-YWCVFVGNSA-N 2-[(3r,5r,6s)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-3-methyl-1-[(2s)-3-methyl-1-propan-2-ylsulfonylbutan-2-yl]-2-oxopiperidin-3-yl]acetic acid Chemical compound C1([C@@H]2[C@H](N(C([C@@](C)(CC(O)=O)C2)=O)[C@H](CS(=O)(=O)C(C)C)C(C)C)C=2C=CC(Cl)=CC=2)=CC=CC(Cl)=C1 DRLCSJFKKILATL-YWCVFVGNSA-N 0.000 claims 1
- 102200055464 rs113488022 Human genes 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361902717P | 2013-11-11 | 2013-11-11 | |
| US61/902,717 | 2013-11-11 | ||
| PCT/US2014/065034 WO2015070224A2 (en) | 2013-11-11 | 2014-11-11 | Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019078325A Division JP2019142916A (ja) | 2013-11-11 | 2019-04-17 | Ｍｄｍ２阻害剤及び１つ以上の追加の医薬活性剤を含む癌治療のための併用療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016535795A JP2016535795A (ja) | 2016-11-17 |
| JP2016535795A5 true JP2016535795A5 (enExample) | 2017-12-21 |
Family
ID=52001089
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016553270A Ceased JP2016535795A (ja) | 2013-11-11 | 2014-11-11 | Ｍｄｍ２阻害剤及び１つ以上の追加の医薬活性剤を含む癌治療のための併用療法 |
| JP2019078325A Pending JP2019142916A (ja) | 2013-11-11 | 2019-04-17 | Ｍｄｍ２阻害剤及び１つ以上の追加の医薬活性剤を含む癌治療のための併用療法 |
| JP2020172367A Expired - Fee Related JP6972274B2 (ja) | 2013-11-11 | 2020-10-13 | Ｍｄｍ２阻害剤及び１つ以上の追加の医薬活性剤を含む癌治療のための併用療法 |
| JP2021178554A Pending JP2022009805A (ja) | 2013-11-11 | 2021-11-01 | Ｍｄｍ２阻害剤及び１つ以上の追加の医薬活性剤を含む癌治療のための併用療法 |
| JP2023003579A Pending JP2023033414A (ja) | 2013-11-11 | 2023-01-13 | Ｍｄｍ２阻害剤及び１つ以上の追加の医薬活性剤を含む癌治療のための併用療法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019078325A Pending JP2019142916A (ja) | 2013-11-11 | 2019-04-17 | Ｍｄｍ２阻害剤及び１つ以上の追加の医薬活性剤を含む癌治療のための併用療法 |
| JP2020172367A Expired - Fee Related JP6972274B2 (ja) | 2013-11-11 | 2020-10-13 | Ｍｄｍ２阻害剤及び１つ以上の追加の医薬活性剤を含む癌治療のための併用療法 |
| JP2021178554A Pending JP2022009805A (ja) | 2013-11-11 | 2021-11-01 | Ｍｄｍ２阻害剤及び１つ以上の追加の医薬活性剤を含む癌治療のための併用療法 |
| JP2023003579A Pending JP2023033414A (ja) | 2013-11-11 | 2023-01-13 | Ｍｄｍ２阻害剤及び１つ以上の追加の医薬活性剤を含む癌治療のための併用療法 |
Country Status (33)
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5631201B2 (ja) | 2007-03-28 | 2014-11-26 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ステッチングされたポリペプチド |
| KR20180058866A (ko) | 2010-08-13 | 2018-06-01 | 에일러론 테라퓨틱스 인코포레이티드 | 펩티도미메틱 거대고리 |
| JP6093770B2 (ja) | 2011-09-27 | 2017-03-08 | アムジエン・インコーポレーテツド | 癌の治療のためのｍｄｍ２阻害剤としての複素環化合物 |
| BR112014009418A2 (pt) | 2011-10-18 | 2017-04-18 | Aileron Therapeutics Inc | macrociclos peptidomiméticos |
| MX2015005244A (es) | 2012-11-01 | 2015-07-14 | Aileron Therapeutics Inc | Aminoacidos disustituidos y metodos de preparacion y el uso de los mismos. |
| US11407721B2 (en) | 2013-02-19 | 2022-08-09 | Amgen Inc. | CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer |
| CA2906538C (en) | 2013-03-14 | 2021-02-02 | Ana Gonzalez Buenrostro | Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer |
| TN2016000176A1 (en) * | 2013-11-11 | 2017-10-06 | Amgen Inc | Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers. |
| AU2015320549A1 (en) | 2014-09-24 | 2017-04-13 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| AU2015320545C1 (en) | 2014-09-24 | 2020-05-14 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and formulations thereof |
| WO2016133194A1 (ja) | 2015-02-20 | 2016-08-25 | 第一三共株式会社 | がんの併用治療法 |
| SG11201707750YA (en) | 2015-03-20 | 2017-10-30 | Aileron Therapeutics Inc | Peptidomimetic macrocycles and uses thereof |
| CN108348520A (zh) * | 2015-08-28 | 2018-07-31 | 诺华股份有限公司 | Mdm2抑制剂和其组合 |
| JP2018528949A (ja) * | 2015-08-28 | 2018-10-04 | ノバルティス アーゲー | Ｐｉ３ｋ阻害剤およびｍｄｍ２阻害剤を使用する組み合わせ療法 |
| WO2017200826A1 (en) * | 2016-05-16 | 2017-11-23 | Albert Einstein College Of Medicine, Inc. | Assays and compounds for treatment of cancer |
| CN118436801A (zh) | 2016-05-20 | 2024-08-06 | 豪夫迈·罗氏有限公司 | Protac抗体缀合物及其使用方法 |
| US20190240210A1 (en) * | 2016-10-17 | 2019-08-08 | Daiichi Sankyo Company, Limited | Treatment Method by Combined Use of MDM2 Inhibitor and DNA Methyltransferase Inhibitor |
| JP7300394B2 (ja) | 2017-01-17 | 2023-06-29 | ヘパリジェニックス ゲーエムベーハー | 肝再生の促進又は肝細胞死の低減もしくは予防のためのプロテインキナーゼ阻害 |
| IL319432A (en) * | 2018-04-30 | 2025-05-01 | Kartos Therapeutics Inc | Methods of treating cancer |
| JP2021525795A (ja) * | 2018-05-25 | 2021-09-27 | カルトス セラピューティクス，インコーポレイテッド | 骨髄増殖性腫瘍を治療する方法 |
| US11091522B2 (en) | 2018-07-23 | 2021-08-17 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| CN110963958B (zh) * | 2018-09-30 | 2025-10-10 | 上海长森药业有限公司 | 一种mdm2抑制剂，及其制备方法、药物组合物和应用 |
| US20220040166A1 (en) * | 2018-12-11 | 2022-02-10 | Kartos Therapeutics | Methods and Compositions of Treating an Ophthalmic Condition |
| CN111434353A (zh) * | 2019-02-02 | 2020-07-21 | 中国科学院上海营养与健康研究所 | Ras抑制剂筛选及疗效标志物 |
| US12194024B2 (en) | 2019-07-26 | 2025-01-14 | Ascentage Pharma (Suzhou) Co., Ltd. | Pharmaceutical composition of MDM2 inhibitor and use thereof for preventing and/or treating disease |
| TW202128156A (zh) * | 2019-11-14 | 2021-08-01 | 美商夸格智財控股有限公司 | 用於癌症治療之btk抑制劑及mdm2抑制劑之組合 |
| US20230218575A1 (en) * | 2020-06-15 | 2023-07-13 | Ascentage Pharma (Suzhou) Co., Ltd. | Microsuspension of an mdm2 inhibitor and therapeautic applications thereof |
| TW202227082A (zh) * | 2020-08-12 | 2022-07-16 | 美商施維雅製藥有限公司 | 用於治療癌症之組合療法 |
| WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
| CN115089585A (zh) * | 2022-08-05 | 2022-09-23 | 中国科学院大学宁波华美医院 | Mdm2抑制剂rg7112联合依托泊苷在治疗肺癌中的应用 |
| WO2024240858A1 (en) | 2023-05-23 | 2024-11-28 | Valerio Therapeutics | Protac molecules directed against dna damage repair system and uses thereof |
| WO2024254156A1 (en) * | 2023-06-05 | 2024-12-12 | Kartos Therapeutics, Inc. | Treatment of endometrial cancer with mdm2 inhibitors |
| WO2025098488A1 (zh) * | 2023-11-09 | 2025-05-15 | 深圳艾欣达伟医药科技有限公司 | 上调p53蛋白表达或激活p53功能的药物与DNA烷化剂联用治疗癌症 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU230251B1 (hu) | 2000-07-19 | 2015-11-30 | Warner-Lambert Co. | 4-Jód-fenil-amino-benzhidroxámsav-észter-származékok és ezeket tartalmazó gyógyászati készítmények |
| WO2006044860A2 (en) | 2004-10-18 | 2006-04-27 | Amgen, Inc. | Thiadiazole compounds and methods of use |
| US7514566B2 (en) | 2006-01-18 | 2009-04-07 | Amgen, Inc. | Thiazole compounds and methods of use |
| DK2139882T3 (en) | 2007-03-23 | 2014-03-10 | Amgen Inc | 3-substituted quinoline or quinoxaline derivatives and their use as inhibitors of phosphatidylinositol 3-kinase (PI3K) |
| EP2132207A2 (en) | 2007-03-23 | 2009-12-16 | Amgen Inc. | Heterocyclic compounds and their uses |
| PL2137186T3 (pl) | 2007-03-23 | 2016-09-30 | Związki heterocykliczne i ich zastosowania | |
| US7625895B2 (en) | 2007-04-12 | 2009-12-01 | Hoffmann-Le Roche Inc. | Diphenyl-dihydro-imidazopyridinones |
| US8557830B2 (en) | 2007-06-07 | 2013-10-15 | Amgen Inc. | RAF kinase modulators and methods of use |
| AU2008276512A1 (en) | 2007-07-17 | 2009-01-22 | Amgen Inc. | Thiadiazole modulators of PKB |
| AU2008276521B2 (en) | 2007-07-17 | 2011-11-03 | Amgen Inc. | Heterocyclic modulators of PKB |
| EP2183232B1 (en) | 2007-08-02 | 2013-03-06 | Amgen, Inc | Pi3 kinase modulators and methods of use |
| EP2231661A1 (en) | 2007-12-19 | 2010-09-29 | Amgen, Inc. | Inhibitors of pi3 kinase |
| BRPI0821209A2 (pt) | 2007-12-19 | 2019-09-24 | Amgen Inc | composto, composição farmacêutica, métodos de tratar câncer, para reduzir o tamanho de tumor, para tratar distúrbios, e para reduzir metástase em um tumor. |
| JP5530422B2 (ja) | 2008-04-07 | 2014-06-25 | アムジエン・インコーポレーテツド | 細胞周期阻害薬としてのｇｅｍ−二置換およびスピロ環式アミノピリジン／ピリミジン |
| MX315904B (es) | 2008-05-30 | 2013-11-29 | Amgen Inc | Inhibidores de fosfoinosituro-3 cinasa. |
| EP2387570A1 (en) | 2009-01-15 | 2011-11-23 | Amgen, Inc | Fluoroisoquinoline substituted thiazole compounds and methods of use |
| AU2010216239B2 (en) | 2009-02-18 | 2012-06-14 | Amgen Inc. | Indole/benzimidazole compounds as mTOR kinase inhibitors |
| MX2011009796A (es) | 2009-03-20 | 2011-12-14 | Amgen Inc | Inhibidores de la cinasa pi3. |
| UY32582A (es) | 2009-04-28 | 2010-11-30 | Amgen Inc | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero |
| CA2760778A1 (en) | 2009-05-13 | 2010-11-18 | Amgen Inc. | Heteroaryl compounds as pikk inhibitors |
| SG176978A1 (en) | 2009-06-25 | 2012-02-28 | Amgen Inc | Heterocyclic compounds and their uses |
| US8765940B2 (en) | 2009-06-25 | 2014-07-01 | Amgen Inc. | Heterocyclic compounds and their uses |
| AR077267A1 (es) | 2009-06-25 | 2011-08-17 | Amgen Inc | Derivados nitrogenados heterociclicos inhibidores selectivos de pi3k, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades inflamatorias y/o autoinmunes. |
| US8754089B2 (en) | 2009-06-25 | 2014-06-17 | Amgen Inc. | Heterocyclic compounds and their uses |
| EP2818170B1 (en) | 2009-09-11 | 2018-12-05 | Amgen, Inc | N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridin yl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer |
| JO2998B1 (ar) * | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
| KR20120031734A (ko) * | 2010-09-27 | 2012-04-04 | 삼성전자주식회사 | 급성 골수성 백혈병 환자의 시타라빈 민감성을 예측하기 위한 키트 및 방법 |
| JP2014503597A (ja) * | 2011-01-31 | 2014-02-13 | セルジーン コーポレイション | シチジンアナログの医薬組成物及びその使用方法 |
| JP6093770B2 (ja) | 2011-09-27 | 2017-03-08 | アムジエン・インコーポレーテツド | 癌の治療のためのｍｄｍ２阻害剤としての複素環化合物 |
| US9216170B2 (en) * | 2012-03-19 | 2015-12-22 | Hoffmann-La Roche Inc. | Combination therapy for proliferative disorders |
| EP2830664A1 (en) | 2012-03-30 | 2015-02-04 | Takeda Pharmaceutical Company Limited | Administration of a raf inhibitor and a mek inhibitor in the treatment of melanoma |
| US20160002185A1 (en) | 2013-02-19 | 2016-01-07 | Amgen Inc. | Cis-morpholinone and other compounds as mdm2 inhibitors for the treatment of cancer |
| MX368703B (es) | 2013-02-28 | 2019-10-11 | Amgen Inc | Un inhibidor de mdm2 derivado de acido benzoico para el tratamiento del cancer. |
| CA2906538C (en) | 2013-03-14 | 2021-02-02 | Ana Gonzalez Buenrostro | Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer |
| JOP20200296A1 (ar) | 2013-06-10 | 2017-06-16 | Amgen Inc | عمليات صنع وأشكال بلورية من mdm2 مثبط |
| EP3024465A1 (en) | 2013-07-26 | 2016-06-01 | Boehringer Ingelheim International GmbH | Volasertib in combination with decitabine for the treatment of acute myeloid leukemia and myelodysplastic syndrome ii |
| TN2016000176A1 (en) * | 2013-11-11 | 2017-10-06 | Amgen Inc | Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers. |
-
2014
- 2014-11-11 TN TN2016000176A patent/TN2016000176A1/en unknown
- 2014-11-11 CN CN202011275297.4A patent/CN112933236A/zh active Pending
- 2014-11-11 SG SG10201902429PA patent/SG10201902429PA/en unknown
- 2014-11-11 KR KR1020217029928A patent/KR102473485B1/ko active Active
- 2014-11-11 LT LTEPPCT/US2014/065034T patent/LT3068393T/lt unknown
- 2014-11-11 SI SI201431961T patent/SI3068393T1/sl unknown
- 2014-11-11 KR KR1020227041845A patent/KR20220167335A/ko not_active Ceased
- 2014-11-11 MX MX2020013670A patent/MX2020013670A/es unknown
- 2014-11-11 PT PT148057433T patent/PT3068393T/pt unknown
- 2014-11-11 KR KR1020167015298A patent/KR102305351B1/ko not_active Expired - Fee Related
- 2014-11-11 AP AP2016009243A patent/AP2016009243A0/en unknown
- 2014-11-11 MX MX2019009853A patent/MX393610B/es unknown
- 2014-11-11 BR BR112016010564A patent/BR112016010564A2/pt not_active IP Right Cessation
- 2014-11-11 MA MA39094A patent/MA39094B1/fr unknown
- 2014-11-11 ES ES14805743T patent/ES2916721T3/es active Active
- 2014-11-11 MY MYPI2016000850A patent/MY192088A/en unknown
- 2014-11-11 EA EA201690980A patent/EA036942B1/ru unknown
- 2014-11-11 RS RS20220533A patent/RS63348B9/sr unknown
- 2014-11-11 AU AU2014346354A patent/AU2014346354A1/en not_active Abandoned
- 2014-11-11 US US15/035,438 patent/US20160287569A1/en not_active Abandoned
- 2014-11-11 CN CN201480072891.XA patent/CN105934255A/zh active Pending
- 2014-11-11 NZ NZ758548A patent/NZ758548A/en not_active IP Right Cessation
- 2014-11-11 EP EP14805743.3A patent/EP3068393B9/en active Active
- 2014-11-11 UA UAA201606309A patent/UA120750C2/uk unknown
- 2014-11-11 PL PL14805743.3T patent/PL3068393T3/pl unknown
- 2014-11-11 EA EA202092456A patent/EA202092456A3/ru unknown
- 2014-11-11 CA CA2930244A patent/CA2930244A1/en active Pending
- 2014-11-11 EP EP22154212.9A patent/EP4039256A1/en not_active Withdrawn
- 2014-11-11 HR HRP20220718TT patent/HRP20220718T1/hr unknown
- 2014-11-11 MX MX2016006025A patent/MX378969B/es unknown
- 2014-11-11 MX MX2020001550A patent/MX391859B/es unknown
- 2014-11-11 HU HUE14805743A patent/HUE059351T2/hu unknown
- 2014-11-11 JP JP2016553270A patent/JP2016535795A/ja not_active Ceased
- 2014-11-11 NZ NZ720766A patent/NZ720766A/en not_active IP Right Cessation
- 2014-11-11 DK DK14805743.3T patent/DK3068393T5/da active
- 2014-11-11 SM SM20220241T patent/SMT202200241T1/it unknown
- 2014-11-11 WO PCT/US2014/065034 patent/WO2015070224A2/en not_active Ceased
-
2016
- 2016-05-06 MX MX2022012320A patent/MX2022012320A/es unknown
- 2016-05-06 MX MX2022008175A patent/MX2022008175A/es unknown
- 2016-05-10 IL IL245568A patent/IL245568B/en unknown
- 2016-05-11 PH PH12016500871A patent/PH12016500871A1/en unknown
- 2016-05-11 CL CL2016001131A patent/CL2016001131A1/es unknown
- 2016-05-17 ZA ZA2016/03342A patent/ZA201603342B/en unknown
-
2018
- 2018-12-21 US US16/229,150 patent/US10881648B2/en not_active Expired - Fee Related
-
2019
- 2019-04-17 JP JP2019078325A patent/JP2019142916A/ja active Pending
-
2020
- 2020-02-24 AU AU2020201321A patent/AU2020201321B2/en not_active Ceased
- 2020-10-13 JP JP2020172367A patent/JP6972274B2/ja not_active Expired - Fee Related
-
2021
- 2021-08-16 IL IL285646A patent/IL285646A/en unknown
- 2021-09-09 US US17/470,136 patent/US20220280495A1/en not_active Abandoned
- 2021-11-01 JP JP2021178554A patent/JP2022009805A/ja active Pending
-
2022
- 2022-03-03 AU AU2022201495A patent/AU2022201495A1/en not_active Abandoned
- 2022-06-08 CY CY20221100397T patent/CY1125358T1/el unknown
-
2023
- 2023-01-13 JP JP2023003579A patent/JP2023033414A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016535795A5 (enExample) | ||
| HRP20220718T1 (hr) | Kombinacijska terapija uključujući inhibitor mdm2 i jedan ili više dodatnih farmaceutski aktivnih sredstava za liječenje raka | |
| CL2019000056A1 (es) | Sales y formas cristalinas del ácido 2-(3r,5r,6s)-5-(3-clorofenil)-6-(4-clorofenil)-1-(s)-1(isopropilsufonil)-3-metilbutan-2-il)-3-metil-2-oxopiperidin-3-il)acético; proceso de preparación de una de las sales; composición farmacéutica que comprende; útiles para tratar cáncer. (solicitud divisional 201503589) | |
| JP2016539157A5 (enExample) | ||
| ME02150B (me) | Derivati piperidinona kao inhibitori mdm2 za lečenje kancera | |
| RU2014120792A (ru) | Способ лечения стромальных опухолей желудочно-кишечного тракта | |
| WO2014179564A8 (en) | Thiazolopyrrolidine inhibitors of ror-gamma | |
| TW201612158A (en) | Amide derivatives and salts thereof, preparation process and pharmaceutical use thereof | |
| MD20170016A2 (ro) | Compuşi aminopirimidinici ca inhibitori JAK | |
| JP2016525102A5 (enExample) | ||
| NZ630589A (en) | Methods of treating alzheimer’s disease and pharmaceutical compositions thereof | |
| JP2017504611A5 (enExample) | ||
| JP2016510326A5 (enExample) | ||
| JP2013542261A5 (enExample) | ||
| PE20170312A1 (es) | Nanoparticulas terapeuticas que comprenden un agente terapeutico, y metodos para su elaboracion y uso | |
| JP2016508134A5 (enExample) | ||
| PH12020550503A1 (en) | Pyridine carbonyl derivatives and therapeutic uses thereof as trpc6 inhibitors | |
| JP2014532647A5 (enExample) | ||
| RU2016141569A (ru) | Комбинации | |
| CY1115725T1 (el) | Ενωσεις, συνθεσεις και μεθοδοι για την θεραπευτικη αγωγη των βητα-αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων | |
| WO2016109217A3 (en) | Btk inhibitors | |
| JP2016523260A5 (enExample) | ||
| MX2014014969A (es) | Combinacion de un inhibidor de la 17-alfa-hidroxilasa (c17,20-liasa) y un inhibidor especifico de la pi-3k para tratar una enfermedad tumoral. | |
| RU2019100037A (ru) | Способ лечения рассеянного склероза с использованием ингибитора lsd1 | |
| JP2011520846A5 (enExample) |